Biocardia announces interim efficacy results in phase iii pivotal cardiamp cell therapy heart failure trial

Sunnyvale, calif., sept. 05, 2023 (globe newswire) -- biocardia®, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced it has finalized external review of interim data and evaluated interim efficacy results for the ongoing phase iii pivotal trial of cardiamp ®  cell therapy for heart failure (cardiamp hf, clinicaltrials.gov identifier: nct02438306), for which the fda granted breakthrough designation for the treatment of heart failure of reduced ejection fraction (hfref).
BCDA Ratings Summary
BCDA Quant Ranking